Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Moodys
Colorcon
Mallinckrodt
AstraZeneca

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for DCC-2618

See Plans and Pricing

« Back to Dashboard

Drug Development Status for DCC-2618: Patents, clinical trial progress, indications

DCC-2618 is an investigational drug.

There have been 23 clinical trials for DCC-2618. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2009.

The most common disease conditions in clinical trials are Gastrointestinal Stromal Tumors, Neoplasms, and Lymphoma. The leading clinical trial sponsors are Deciphera Pharmaceuticals LLC, National Heart, Lung, and Blood Institute (NHLBI), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Recent Clinical Trials for DCC-2618
TitleSponsorPhase
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibDeciphera Pharmaceuticals LLCPhase 3
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals LLCPhase 1/Phase 2

See all DCC-2618 clinical trials

Clinical Trial Summary for DCC-2618

Top disease conditions for DCC-2618
Top clinical trial sponsors for DCC-2618

See all DCC-2618 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
Colorcon
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.